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A Brief Adherence Intervention that Improved Glycemic Control: Mediation by
Patterns of Adherence
Abstract
This study examined whether longitudinal adherence profiles mediated the relationship between a brief
adherence intervention and glycemic control among patients with type 2 diabetes. Adherence was
assessed using the Medication Event Monitoring System. Longitudinal analysis via growth curve mixture
modeling was carried out to classify patients according to patterns of adherence to oral hypoglycemic
agents. Hemoglobin A1c assays were used to measure glycemic control as the clinical outcome. Across
the whole sample, longitudinal adherence profiles mediated 35.2% (13.2, 81.0%) of the effect of a brief
adherence intervention on glycemic control [from odds ratio (OR) = 8.48, 95% confidence interval (CI)
(3.24, 22.2) to 4.00, 95% CI (1.34, 11.93)]. Our results suggest that patients in the intervention had better
glycemic control largely due to their greater likelihood of adherence to oral hypoglycemic agents.

Keywords
primary health care, type 2 diabetes, adherence, randomized controlled trials, mediation

Disciplines
Business | Health and Medical Administration | Health Services Administration | Health Services Research
| Medical Humanities | Statistics and Probability

This technical report is available at ScholarlyCommons: https://repository.upenn.edu/statistics_papers/632

NIH Public Access
Author Manuscript
J Behav Med. Author manuscript; available in PMC 2016 February 01.

NIH-PA Author Manuscript

Published in final edited form as:
J Behav Med. 2015 February ; 38(1): 39–47. doi:10.1007/s10865-014-9576-3.

A Brief Adherence Intervention that Improved Glycemic Control:
Mediation by Patterns of Adherence
Heather F. de Vries McClintock, M.S.P.H.1, Knashawn H. Morales, Sc.D.2, Dylan S. Small,
Ph.D.3, and Hillary R. Bogner, M.D., M.S.C.E.
1Department

of Family Medicine and Community Health, University of Pennsylvania,
Philadelphia, PA, U.S.A
2Center

for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA,

U.S.A
3Department

of Statistics, The Wharton School, The University of Pennsylvania, Philadelphia, PA,

NIH-PA Author Manuscript

U.S.A

Abstract
This study examined whether longitudinal adherence profiles mediated the relationship between a
brief adherence intervention and glycemic control among patients with Type 2 diabetes.
Adherence was assessed using the Medication Event Monitoring System (MEMS). Longitudinal
analysis via growth curve mixture modeling was carried out to classify patients according to
patterns of adherence to oral hypoglycemic agents. Hemoglobin A1c (HbA1c) assays were used to
measure glycemic control as the clinical outcome. Across the whole sample, longitudinal
adherence profiles mediated 35.2% (13.2%, 81.0%) of the effect of a brief adherence intervention
on glycemic control (from odds ratio (OR) = 8.48, 95% CI (3.24, 22.2) to 4.00, 95% CI (1.34,
11.93)). Our results suggest that patients in the intervention had better glycemic control largely
due to their greater likelihood of adherence to oral hypoglycemic agents.
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INTRODUCTION
Interventions targeting adherence to medications for diabetes have been successful in
improving clinical outcomes (Vermeire et al., 2005). However, the factors comprising an
effective adherence intervention have yet to be fully elucidated. Evidence suggests that
interventions tailored specifically to the individual which address a wider range of barriers
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may be the most effective in producing clinically meaningful results (e.g. (Haynes et al.,
2008)). Education alone has not been found to be sufficient for producing significant
behavior change (Mundt et al., 2001). While many adherence enhancing interventions have
succeeded in improving glycemic control, it remains unclear whether improved glycemic
control results from improved patient adherence.
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The focus of intervention research on “do they work?” not “why do they work?” leaves a
substantial gap in understanding what comprises a successful adherence intervention.
Mediation analysis is an important method for examining the mechanism of intervention
trials. A mediator accounts for the variation between a predictor and an outcome, while
moderators indicate when effects might be seen, mediators specify how or why an effect
occurred (Baron & Kenny, 1986). Given findings that interventions improve adherence, and
interventions improve clinical outcomes, the investigation of whether improvements in a
clinical outcome are due to improvements in adherence occasioned by the intervention is an
important next step in scientific inquiry (Stratton et al., 2000; Turner et al., 1999). Prior
work has found that diabetes adherence interventions improve adherence and glycemic
control but these studies have not examined mediation by medication adherence (e.g. (Aliha
et al., 2013; J. D. Piette et al., 2000)). Determinants of behavior change (e.g. socioecological resources and self-efficacy) have been examined in relation to diabetes
intervention effects on behaviors and clinical outcomes (Barrera et al., 2008; Sweet et al.,
2009; Trief et al., 2009). Mediation of diabetes intervention effects on clinical outcomes by
behavior (e.g. insulin use and self-monitoring practices) has also been investigated (Brega et
al., 2012; J. Piette et al., 2013). Only one identified study examined the influence of
adherence behavior to diabetes self-care as a mediator of an intervention’s effect on glucose
control (Trief et al., 2013). To our knowledge, no known studies have examined mediation
of a diabetes intervention effect by longitudinal profiles of oral hypoglycemic agent
adherence.
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Our goal was to examine longitudinal profiles of oral hypoglycemic adherence as a mediator
of a brief adherence intervention on glycemic control. The model in Figure 1 represents a set
of testable hypotheses about how the intervention and improved glucose control may be
related to one another through their association with oral hypoglycemic agent adherence
profile type. Our model was tested in four stages: 1) the association of intervention
assignment and glucose control; 2) the association of intervention assignment with oral
hypoglycemic agent adherence profile type; 3) the association of adherence profile type and
glucose control; and 4) the association of intervention and improved glucose control with
terms representing oral hypoglycemic agent adherence profile type in the model to test for
mediation.

METHODS
Study Sample
A Brief Intervention to Improve Adherence through Integrated Management of type 2
Diabetes Mellitus and Depression Treatment was a randomized controlled trial designed to
examine whether an integrated care intervention (IC intervention) improved adherence to
oral hypoglycemic agents, glycemic control, and depression among primary care patients
J Behav Med. Author manuscript; available in PMC 2016 February 01.
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with type 2 diabetes mellitus (type 2 DM). The study protocol was approved by the
University of Pennsylvania Institutional Review Board. The intervention is described in
detail elsewhere (Bogner et al., 2012).
Recruitment
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Patients were recruited from three primary care practices in Philadelphia, Pennsylvania.
From April 2010 to April 2011, patients with a diagnosis of type 2 DM and a prescription
for an oral hypoglycemic agent within the past year were identified through electronic
medical records. Patients with an upcoming appointment who met initial criteria were
approached for further screening. Eligibility criteria included: 1) aged 30 years and older; 2)
a diagnosis of type 2 DM; 3) a current prescription for an oral hypoglycemic agent; and 4) a
current prescription for an antidepressant. The age cut-off of 30 years and older was chosen
because of its significance for the detection, screening, and intervention for diabetic patients
(Kahn et al., 2010). Patients with a current prescription for an antidepressant were included
because diabetes and depression are two of the most common co-morbid problems seen in
primary care settings (Eaton, 2002). Exclusion criteria included: 1) inability to give
informed consent; 2) significant cognitive impairment at baseline (Mini-Mental State
Examination (MMSE) <21) (Crum et al., 1993); 3) residence in a care facility that provides
medications on schedule; and 4) unwillingness or inability to use the Medication Event
Monitoring System (MEMS). The intervention aimed to address adherence to patients’
entire medication treatment regimen including insulin use, and thus insulin users were not
excluded from participation. Patients whose caregivers assisted with their medications were
not excluded from participation. MEMS caps on pill bottles record the exact data and time
of medication container opening. Patients were randomly assigned to the IC intervention or
usual care.
Study Design
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This trial consisted of two phases: the run-in phase and the randomized controlled trial
phase. The purpose of the 2-week run-in phase was to collect pre-intervention adherence
rates for all patients. During this phase data were also collected on demographics, depressive
symptoms, and glycosylated hemoglobin. No intervention was performed during this phase.
Following completion of the 2-week run-in phase, patients entered phase 2 of the study in
which they were randomized within each practice by flip of a coin to either the IC
intervention or usual care. Physicians were told which patients were enrolled in the IC
intervention to allow for collaboration with the IC manager, but were blinded to enrollment
in the usual care group.
Integrated Care Intervention (IC Intervention)
For patients assigned to the intervention, integrated care managers offered education,
guideline-based treatment recommendations, and monitored adherence and clinical status in
collaboration with physicians. The integrated care manager worked with patients
individually to address patient-level factors involved in adherence to oral hypoglycemic
agents including depression, chronic medical conditions, function, cognition, lack of social
support, cost of medications, experiencing side effects, and past experiences with
medications. Patient-level factors were addressed through a variety of activities including in
J Behav Med. Author manuscript; available in PMC 2016 February 01.
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person sessions, telephone contacts, and collaborating with the physician. Through in person
sessions and telephone conversations the IC manager provided education about type 2 DM;
helped patients identify target symptoms; provided a rationale for the rationale for use of
oral hypoglycemic agents; assessed for side-effects and needed assistance with selfmanagement; assessed for progress (e.g. improvement in finger stick results); assisted with
referrals; and monitored and responded to life-threatening symptoms (e.g. chest pain). The
intervention was presented to patients as a supplement to, rather than a replacement for,
existing primary care treatment.
Over a three-month period patients had three 30-minute in person sessions (baseline, 6
weeks and 12 weeks) and two 15-minute telephone monitoring contacts. Integrated care
managers were two research coordinators (one Master’s level and one bachelor’s level) who
administered all intervention activities. Prior to trial initiation, the integrated care managers
received training on pharmacotherapy for type 2 DM management during weekly clinical
sessions with the principal investigator.
Usual Care
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Patients in the usual care group underwent the same assessments at the same time points
(baseline, 6, and 12 weeks) as the patients in the IC intervention. As in the intervention
group, assessments were conducted in person. Research assistants conducted all assessments
and were blinded to patients’ randomization status.
Measurement Strategy
Potential study patients were screened for cognitive impairment using the MMSE, a short
standardized mental status examination widely employed for clinical and research purposes
(Folstein et al., 1975). Patients were asked whether they resided in a care facility that
provided medications on schedule and whether they were unwilling or unable to use MEMS.
At baseline sociodemographic characteristics were assessed using standard questions.
Functional status was measured using the Medical Outcomes Study Short Form (SF-36)
(Stewart et al., 1988). Adherence to oral hypoglycemic agents was measured during the 2week run-in phase, and at 6 and 12 weeks, using electronic monitoring data obtained from
MEMS Caps.
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At baseline and 12 weeks blood glycemic control was assessed in accordance with American
Diabetes Association Guidelines (American Diabetes Association, 2014). Hemoglobin A1c
(HbA1c) assays were performed with the in2it A1C Analyzer. Point of care testing using this
device has acceptable precision and agreement in comparison with laboratory services
(Moridani et al., 2003).
Analytic strategy
We calculated descriptive statistics to compare baseline patient characteristics in the
intervention group to usual care using the Fishers’ exact test and Wilcoxon rank sum test
(for categorical and continuous variables respectively). For the analysis of mediation, we
used our prior classifications of patients into latent longitudinal adherence profile (de Vries
McClintock et al., in press). To obtain these profiles, we employed recent developments in

J Behav Med. Author manuscript; available in PMC 2016 February 01.
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statistical assessment of treatment effects or of course of depression in primary care,
especially the general growth curve mixture model (GGCMM) (Jo & Muthen, 2001; B.
Muthen et al., 2002; B. O. Muthen, 2001; B. O. Muthen & Shedden, 1999) as in prior work
(e.g. (Elliott et al., 2005; Lin et al., 2007)). Binary indicators of adherence measurements
were assessed by MEMS caps at weekly intervals over a 12-week period. Patients were
categorized as adherent if they took at least 80% of their pills in the interval (George et al.,
2000). Otherwise, patients were considered to be nonadherent. The GGCMM analyses
produced parameters that describe the adherence profiles of each class as well as estimated
posterior probabilities of unobserved class membership for each patient. Patients were
classified into categories of longitudinal adherence profile types based on the largest
posterior probability of membership across the classes. Longitudinal adherence profile types
identified were: adherent, increasing adherence, and nonadherent. We analyzed the resulting
categorical variable for longitudinal oral hypoglycemic agent adherence profile types as a
mediator.
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The 4-step approach of Baron and Kenny provides a theoretical and practical foundation for
the assessment of mediation (Baron & Kenny, 1986). The definition of mediation is met if
the following conditions hold: 1) the IC intervention improves the clinical outcome (blood
glucose control); 2) the IC intervention improves the potential mediator (longitudinal oral
hypoglycemic agent adherence profile type); 3) improvements in the mediator are associated
with improvements in the clinical outcome, controlling for the intervention's effect on the
outcome; and 4) adjusting for the mediator, the clinical outcome is attenuated and no longer
significant. Partial mediation is present if the intervention coefficient is attenuated but there
is still a significant effect of the intervention on glucose control. An additional requirement
of causal mediation is that changes in the mediators occur in time before changes in the
outcome. Adherence is measured over time before the outcome of interest, blood glucose
control. Following MacKinnon et al., we used a threshold of 15% for sufficient change in
the coefficients of intervention as assessment of attenuation for mediation (D. P. MacKinnon
et al., 2000; D. P. MacKinnon et al., 2002). The first three conditions have been examined in
prior work, and meet sufficient criteria for mediation (Bogner et al., 2012; de Vries
McClintock et al., in press). For condition 2, patients in the intervention condition were
more likely to have an adherent pattern compared to a nonadherent pattern (OR = 11.6, 95%
CI [4.08, 32.9]). Patients in the intervention condition were more likely to have an
increasing adherence pattern compared to a nonadherent pattern (OR= 41.31, 95% CI
[13.87, 123.03]) (de Vries McClintock et al., in press). For this analysis we are examining
whether criteria for condition number 4 is met.
Based on our prior work examining the relationship between intervention condition and
glucose control, patients were analyzed according to the treatment to which they were
randomized (intent-to-treat). Practice site was included in the model to account for
unmeasured factors related to clustering by practice. The model adjusted for baseline HbA1c.
Logistic regression related latent class variables to the clinical outcome of glucose control at
12 weeks for the entire sample. To assess whether stratified analysis was warranted we
examined baseline interactions (Baron & Kenny, 1986). Based on the presence of a
significant interaction (p<.001), we then conducted stratified analysis of patients with and
without HbA1c ≥8% at baseline. As recommended by clinical guidelines, our outcome of
J Behav Med. Author manuscript; available in PMC 2016 February 01.
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glucose control was assessed using a cutoff of HbA1c < 7% at 12 weeks (American Diabetes
Association, 2014). The results are presented in the form of odds ratios and 95% confidence
intervals. As recommended by Hayes (Hayes, 2009), we have modernized the application of
Baron and Kenny by applying the bootstrapping technique, one of the more valid and
powerful methods for testing intervening variable effects and generating bias-corrected
confidence intervals for indirect effects. The size of the indirect effect and bias-corrected
95% CI was obtained through the bootstrap techniques with 5000 replications (Preacher &
Hayes, 2008; Vanderweele & Vansteelandt, 2010). We set α at 0.05, recognizing that tests
of statistical significance are approximations that serve as aids to inference. The GGCMM
was fitted using Mplus version 7 (Muthén & Muthén, 1998) and other analyses were
conducted in STATA version 12 for Windows (STATA Corporation, College Station, TX).

RESULTS
Study sample
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The CONSORT flow diagram for this trial has been published elsewhere (Bogner et al.,
2012). In brief, of 715 patients with type 2 DM were identified by electronic medical
records. In all, 265 were eligible based on initial inclusion criteria and approached, and 190
were enrolled based on additional inclusion criteria (71.7% participation rate). After a 2week run-in phase in which adherence to medications was assessed, consent was obtained.
At the 2-week visit, 8 patients were no longer eligible for participation (5 physicians had
discontinued antidepressants, 1 physician had discontinued an oral hypoglycemic agent, and
2 patients were lost to follow-up). The remaining 182 patients were randomized to the IC
intervention or usual care. Subsequently, 2 patients in the IC intervention were lost to
follow-up leaving 180 patients who completed all study visits. For these 180 patients
complete information on baseline covariates and on the clinical outcome of glucose control
at 12 weeks was obtained. The mean age of our sample was 57.4 years (standard deviation
(s.d.) 9.5 years, range 32 to 84 years). One hundred and twenty-two (67.8%) of the patients
were women. The self-identified race of patients was 65 white (36.1%), 102 AfricanAmerican (56.7%), 7 Hispanic (3.9%), and 6 (3.3%) who self-identified as ‘other.’ In all, 69
persons (38.33%) were married and 29 persons (16.1%) had less than a high school
education. The mean number of medical conditions was 7.3 (s.d. 3.2) and the mean MMSE
score was 28.2 (s.d. 2.3). The baseline patient characteristics of the study sample are shown
in Table 1.
Mediation of intervention group effect on glycemic control by adherence profile type
In our prior work, a series of general growth curve mixture models (GGCMM) were fitted to
the MEMS data. The three-pattern model presented in Figure 2 improved the model fit over
the two- and four-pattern models yielding three adherence profile types. The three adherence
profile types identified and employed for this analysis were: adherent (n=67), increasing
adherence (n=52), and nonadherent (n=61) (de Vries McClintock et al., in press). Table 2
shows the effect of the intervention on glycemic control in models with and without
mediation by adherence profile types. Patients randomized to the IC intervention were more
likely to achieve a HbA1c <7% in comparison with patients in the usual care group at 12
weeks (p<0.001). When including the mediator (adherence profile type) in the model
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evaluating achievement of HbA1c <7% at 12 weeks, 35.2%, (95% confidence interval (CI)
(13.2%, 81.0%)) of the effect was mediated by adherence profile type (from odds ratio (OR)
= 8.48, 95% CI (3.24, 22.2) to 4.00, 95% CI (1.34, 11.93)) (Table 2).
Mediation of intervention group effect on glycemic control by adherence profile type
stratified by HbA1c ≥ 8%
Additional multivariate analyses were performed to examine mediation by patients with and
without HbA1c ≥8%. Among patients with HbA1c ≥8%, patients randomized to the IC
intervention were more likely to achieve an HbA1c <7% in comparison with patients in the
usual care group at 12 weeks (intervention 25.0% vs. usual care 4.8%; p<0.05). When
including the mediator (adherence profile type) in the model evaluating achievement of
HbA1c <7% at 12 weeks, 63.5% of the effect was mediated by adherence profile type and
the relationship between the intervention and glucose control was no longer significant
(from OR=12.41, 95% CI (1.21, 654.35) to 2.51, 95% CI (0.12, 159.82)).
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Among patients with an HbA1c <8%, patients randomized to the IC intervention were more
likely to achieve HbA1c <7% in comparison with patients in the usual care group at 12
weeks (intervention 89.7% vs. usual care 62.7%; p<0.01). When including the mediator
(adherence profile type) in the model evaluating achievement of HbA1c <7% at 12 weeks,
only 26.4% of the effect was mediated by adherence profile type (from OR= 4.77, 95% CI
(1.87, 12.17) to 3.16, 95% CI (1.05, 9.49)).

DISCUSSION
The principal finding of this study is that the relationship between a brief adherence
intervention and glycemic control was partially mediated by oral hypoglycemic agent
adherence profile type over 12 weeks across the entire sample. Among patients with a
HbA1c ≥8% at baseline, the relationship between the brief adherence intervention and
glycemic control was fully mediated by oral hypoglycemic agent adherence profile type
over 12 weeks. A brief intervention’s effect on improved glycemic control among patients
with a HbA1c ≥8% was due to their greater likelihood of adherence to oral hypoglycemic
agents. To our knowledge, this is the first report of mediation by adherence of an association
between a diabetes adherence intervention and glycemic control.
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Before discussing the implications of our findings, the limitations of our study must be
considered. First, our results were obtained from patients who received care at three primary
care sites that might not be representative of most primary care practices. However, the three
practices were diverse and varied in size and were probably similar to other primary care
practices in the region. Second, all methods for assessing adherence have limitations. We
chose to use microelectronic monitors on pill bottles as our primary measure of adherence
because microelectronic monitors have a low failure rate (George et al., 2000) and may be
more sensitive than other adherence measures (Farmer, 1999). The validity and reliability of
electronic monitoring of adherence provides a reference standard by which other adherence
assessment methods can be examined (Nakonezny et al., 2008; Osterberg & Blaschke,
2005). Third, while the 80% threshold for adherence has been assessed in some clinical
research (e.g.(George et al., 2000)), the clinical relevance of this threshold has not been
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tested for many medications. Fourth, we utilized only one method of mediation analysis.
Other approaches to mediation analysis (Hayes, 2009) with different assumptions may yield
different results (D. Mackinnon, 2008). Fifth, a current prescription for an antidepressant
was part of our inclusion criteria. Therefore, our findings may be most relevant to patients
with diabetes as well as depression. Finally, point-of-care testing for HbA1c, is imperfect in
its assessment (Lenters-Westra & Slingerland, 2010). However, misclassification would
likely be nondifferential thus biasing estimates toward the null. Drawbacks of point of care
testing for HbA1c must be weighed in relation to other factors such as cost-effectiveness and
practicality of use in the clinical setting.
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Despite limitations, our results deserve attention because we attempted to characterize the
relationship between a brief adherence intervention, oral hypoglycemic agent adherence
profile type and glycemic control. Our work is consistent with Trief et al. who found that a
telemedicine case management intervention among patients with type 2 DM was mediated
by self-reported adherence to diabetes self-care. Trief and colleagues examined mediation
by self-reported adherence to recommended blood glucose testing, dietary control, exercise,
and foot care. In contrast, the focus in our study was on adherence to medications for
diabetes because of the clinical significance of diabetes medication taking in clinical
prognosis (Rasmussen et al., 2007). Our use of general growth curve mixture models
allowed us to distinguish distinct patterns of adherence over time instead of assessing
adherence through proportions at singular point(s) in time with no assessment of variation
over time and group classification. Furthermore, this approach utilizes all adherence data
producing estimated posterior probabilities of unobserved class membership for each
patient, thus improving precision by accounting for effects of the intervention and baseline
covariates on adherence. In summary, our findings build and expand on prior work by
demonstrating that longitudinal adherence profiles assessed by an objective measure of
medication adherence mediate the relationship between a brief adherence intervention and
glycemic control for patients with HbA1c ≥8% at baseline.
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Specifically, in our examination across the full sample, our results demonstrate partial
mediation. While the intervention coefficient is attenuated, there is still a significant
relationship between the intervention and glucose control. Partial mediation may be due to
the comprehensive nature of the adherence intervention in which adherence barriers were
targeted using a multi-faceted approach. Improved glycemic control may have occurred
through mechanisms other than improved adherence (e.g. diet and exercise) as the
interventionist aimed to improve through an array of avenues including social support and
the development of problem solving skills. In addition, the therapeutic alliance, defined
broadly as the collaborative bond between patient and provider, has been identified as a key
element of patient-provider relationship not only for psychotherapy, but also for
pharmacotherapy. Better therapeutic alliance is associated with better adherence to
medications as well as treatment outcomes (Krupnick et al., 1996; McCabe et al., 2012). The
therapeutic alliance may be tapping into patient’s subjective assessment of the social and
personal experiences with their provider or in this case the interventionist. If patients had a
stronger bond with an interventionist, they may be more willing to follow the
interventionist’s advice on treatment adherence and, in turn, may have been more adherent
leading to better clinical outcomes.
J Behav Med. Author manuscript; available in PMC 2016 February 01.
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Our finding that mediation was present to a greater extent for patients with a HbA1c ≥8%
compared to patients with a HbA1c <8% at baseline supports a more complex
conceptualization of mediation effects in which mediators may differ by baseline
characteristics of the patient. It may be necessary to develop interventions that incorporate
mediators based on individual patients. In other words, some mediators may work for some
patients but not for others, and intervention development may need to be customized
accordingly. Mediators of intervention effect have been identified as factors that may be
critical for tailoring (Small et al., 2012). Methodological developments allow for tailoring
over time throughout the interval of intervention deployment, even for covariates that occur
post-randomization (Almirall et al., 2012). Further research with such designs (e.g. adaptive
trials) may have both important methodological and clinical implications.
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Building on prior evidence indicating that interventions targeting adherence improve clinical
outcomes (e.g. (Vermeire et al., 2005)), we have sought to help elucidate the mechanism by
which interventions may influence outcomes. Our results indicate that patterns of adherence
over time are critical in explaining diabetes intervention effects on glycemic control. The
prospective design of the study lends strength to the idea that patterns of adherence over
time can signal how effective an intervention may be in improving outcomes. Patterns of
adherence over time may be an important marker for subsequent clinical outcomes and
therefore are an important target for intervention and follow-up.
The National Institutes of Health (NIH) Adherence Research Network has identified
improving adherence as a top priority. This inter-disciplinary initiative notes that increased
adherence to medication regimens promises substantial improvements in public health as
well as savings in healthcare costs. A lack of compliance with recommended treatment
regimens has been identified as a causal factor in preventable morbidity and mortality in
numerous studies and across many illnesses (Osterberg & Blaschke, 2005). Thus, efforts to
improve treatment adherence has been labeled the "next frontier in (healthcare) quality
improvement"(Heidenreich, 2004). Our study provides additional evidence of the public
health importance of addressing adherence. The effectiveness of diabetes interventions in
improving clinical outcomes may be substantially mediated by patterns of adherence over
time. Collaborative networks between policy initiatives, healthcare networks and medical
settings are needed to develop sustainable adherence programs.
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Figure 1.
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Model of the potential relationship of the intervention, oral hypoglycemic agent adherence
profile type, and glycemic control.
Note: Oral hypoglycemic agent adherence profile types were obtained from general growth
curve mixture models in which patients were classified into categories of longitudinal
adherence profile types based on the largest posterior probability of membership across the
classes. Three longitudinal adherence profile types were: adherent, increasing adherence,
and nonadherent.
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Figure 2.

General growth curve mixture model analysis of adherence to oral hypoglycemic agents
(number of patients in each class with plotted conditional probabilities) (n=180).
Note: Data gathered from 2010–2011.
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Baseline characteristics. P-values represent comparisons according to Fisher’s Exact test and the Wilcoxon
rank sum test for categorical or continuous data, respectively.
Usual Care
(n=88)

Intervention
(n=92)

P
value

.75

Sociodemographic characteristics
Age, mean in years (s.d.)

57.1 (9.6)

57.8 (9.4)

African American, n (%)

48 (54.5%)

54 (58.7%)

White, n (%)

36 (40.9%)

29 (31.5%)

3 (3.4%)

4 (4.3%)

Hispanic, n (%)
Other, n (%)

.28

1 (1.1%)

5 (5.4%)

Gender, women n (%)

58 (65.9%)

64 (69.6%)

.64

Less than HS education, n (%)

15 (17.0%)

14 (15.2%)

.84

12.0 (11.8)

10.5 (10.2)

.37

HbA1c, mean (s.d.)

7.0 (1.9)

7.2 (1.8)

.22

PHQ-9, mean (s.d.)

9.9 (7.2)

10.6 (7.9)

.65

Type 2 diabetes mellitus
Years of diabetes, mean (s.d.)

NIH-PA Author Manuscript

Depression

Medications
Number of medications, mean (s.d.)

10.1 (5.1)

9.8 (4.5)

.71

≥ 80% adherent to oral hypoglycemic agent, n (%)

37 (42.0%)

33 (35.9%)

.45

Physical function score, mean (s.d.)

53.6 (31.7)

50.8 (32.6)

.57

Social function score, mean (s.d.)

67.7 (39.9)

76.6 (36.9)

.09

Functional status (SF-36)

NIH-PA Author Manuscript

Role physical score, mean (s.d.)

49.4 (46.7)

59.5 (46.6)

.15

Role emotional score, mean (s.d.)

65.9 (46.0)

67.8 (44.6)

.82

Bodily pain score, mean (s.d.)

42.3 (31.4)

50.9 (31.7)

.06

MMSE, mean (s.d.)

28.2 (2.3)

28.2 (2.3)

.80

Cognitive status

Abbreviations: s.d., standard deviation; HS, high school; SF-36; Medical Outcomes Study Short Form; MMSE, Mini-Mental State Examination;
PHQ-9, nine-item Patient Health Questionnaire; Hb, hemoglobin.
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43 (48.9)

67 (72.8)

Intervention
(n=92)

8.48 (3.24 to 22.2)†

Estimated
Between-Group
Odds Ratio*
(95% CI)

<0.001

P
value

4.00 (1.34, 11.93)†

Estimated
Between-Group
Odds Ratio**
(95% CI)

With mediator
(adherence profile
type)

.013

P
value

Adjusted for baseline glycosylated hemoglobin, primary care practice and pattern of adherence

**

Adjusted for baseline glycosylated hemoglobin and primary care practice

Odds ratio (95% CI) from a logistic regression model.

*

†

Abbreviations: CI, confidence interval; s.d., standard deviation; Hb, hemoglobin. Estimates, 95% confidence intervals, and p-values from the statistical models.

Achieved HbA1c < 7%, n (%)

Type 2 diabetes mellitus

Usual Care
(n=88)

Unadjusted Estimate

Without mediator
(adherence profile
type)

Clinical outcomes of glycemic control in usual care and in the integrated intervention at 12 weeks.
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